Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 01, 2026
TickeronGET DAILY SIGNALS
TELUS (TU): Q1 2026 Earnings Preview Amid Steady Demand and Sector Pressures

TELUS (TU): Q1 2026 Earnings Preview Amid Steady Demand and Sector Pressures

Key Takeaways

  • Analysts forecast Q1 2026 revenue at C$5.06 billion, roughly flat year-over-year from Q1 2025's C$5.06 billion.
  • Consensus EPS estimate stands at US$0.16, reflecting cautious expectations amid competitive pressures.
  • Key metrics to watch include postpaid mobile net additions, broadband subscriber growth, and TELUS Health revenue expansion.
  • Management's 2026 guidance targets 2-4% growth in service revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
  • Free cash flow (FCF) outlook of ~C$2.45 billion supports ongoing dividend payments.
  • Shares trade near 52-week lows at ~US$12.53, up slightly YTD but pressured by sector dynamics.

Earnings Context and Why It Matters

TELUS Corporation, a leading Canadian telecommunications provider, is heading into Q1 2026 earnings with its diversified portfolio across mobility, broadband, and high-growth TELUS Health services. After the Q4 2025 EPS miss of US$0.15 against expectations of US$0.18, but with solid full-year 2025 revenue of C$20.3 billion, investors are looking for reassurance on the company's 2026 targets. This report carries weight given the intense competition in telecom, regulatory attention on pricing, and macroeconomic challenges such as inflation. In my view, robust performance in the Health segment could help counterbalance core telecom headwinds, highlighting TELUS's shift toward digital health and AI-driven solutions. For shareholders, updates on customer metrics and guidance will be key to assessing dividend sustainability and deleveraging efforts.

Earnings Expectations

Analysts expect consolidated revenue of C$5.06 billion for the quarter ended March 31, 2026, holding steady with Q1 2025 levels as service demand remains consistent. The EPS consensus sits at US$0.16 based on 13 analysts' estimates, a slight dip from Q1 2025's US$0.19 that beat expectations. Key areas to monitor include postpaid mobile net additions, with TELUS targeting industry-leading churn below 1%, PureFibre broadband connections, and TELUS Health revenue growth, which reached 13% in Q4 2025. I also checked this using Tickeron’s AI Screener to see how TU compares to peers on these metrics.

TELUS has a track record of mixed EPS surprises—missing in Q4 2025 but beating in Q1 2025. Stock reactions have been varied: shares climbed after Q1 2025 results but fell following Q4 guidance, even with some positive beats. Updates on 2026 targets, including 2-4% service revenue growth and C$2.45 billion in FCF, will be critical.

Market Reaction and Investor Sentiment

With Q1 earnings set for May 8, sentiment around TU remains cautious. Shares are lingering near 52-week lows at around US$12.53, posting modest year-to-date gains of about 2%, weighed down by pricing pressures and competition from BCE and Rogers in the telecom sector. Analysts highlight risks from possible rate hikes or soft subscriber growth, but there's optimism about TELUS Health's momentum and the 2026 FCF trajectory. Historically, post-earnings moves have ranged from 2-5% in recent quarters, underscoring the potential for volatility.

Discovering Opportunities with Tickeron’s AI Screener

One tool I rely on regularly for my research is Tickeron’s AI Screener, an AI-powered platform for discovering stocks and ETFs. It lets me filter thousands of names using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—covering industry, market cap, indicators, price patterns, and performance metrics. This streamlines finding trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual scans. From what I see, it's particularly useful for analyzing telecom names like TU against the broader market.

Forward Outlook and Key Factors to Monitor

Following Q1 results, watch for management to reaffirm 2026 guidance, with 2-4% growth in service revenue and adjusted EBITDA. TELUS's deleveraging efforts—aiming for a lower net debt-to-EBITDA ratio—will be important in the current high-interest-rate environment.

On the operations side, key catalysts include wireless postpaid net additions and churn rates, where TELUS outperforms peers at about 0.9% in Q4 2025. The PureFibre broadband rollout continues as a priority, backed by investments in 5G and fiber expansion.

In TELUS Health, look for continued revenue acceleration from acquisitions and AI integrations, building on the 13% Q4 growth. Broader factors like regulatory decisions on pricing and consumer spending on premium plans may squeeze margins. The FCF path to C$2.45 billion supports the roughly 9% dividend yield, which draws income-focused investors.

Looking ahead, catalysts include Q2 results in August, possible M&A in health, and advancement toward the three-year goal of 10%+ FCF CAGR through 2028. I'm watching these developments closely.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: TU

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TU in upward trend: price rose above 50-day moving average on October 30, 2026

TU moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 12 of 25 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 48%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TU's RSI Oscillator exited the oversold zone, 20 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 48%.

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TU as a result. In 25 of 70 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 36%.

The Moving Average Convergence Divergence (MACD) for TU just turned positive on October 13, 2026. Looking at past instances where TU's MACD turned positive, the stock continued to rise in 13 of 37 cases over the following month. The odds of a continued upward trend are 35%.

The 10-day moving average for TU crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 36%.

Following a +4.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where TU advanced for three days, in 117 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 42%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.

TU broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TU entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. TU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.055) is normal, around the industry mean (2.078). P/E Ratio (-15.345) is within average values for comparable stocks, (-4.900). Projected Growth (PEG Ratio) (13.443) is also within normal values, averaging (8.005). Dividend Yield (0.061) settles around the average of (0.125) among similar stocks. P/S Ratio (0.951) is also within normal values, averaging (5.777).

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Verizon Communications (NYSE:VZ), AT&T (NYSE:T), Comcast Corp (NASDAQ:CMCSA), Lumen Technologies (NASDAQ:LUMN).

Industry description

Major telecommunications include companies that make communication possible across the globe – by providing voice and data transmission via multiple channels such as phone or the Internet, through airwaves or cables, through wires or wirelessly. The ease with which we connect with anyone, anywhere in the world is thanks in large part to the infrastructure created by the telecom industry. Some major telecom players include AT&T Inc., Verizon Communications Inc. and Nippon Telegraph and Telephone Corporation.

Market Cap

The average market capitalization across the Major Telecommunications Industry is 17.42B. The market cap for tickers in the group ranges from 714.84K to 225.96B. SFTBY holds the highest valuation in this group at 225.96B. The lowest valued company is CPROF at 714.84K.

High and low price notable news

The average weekly price growth across all stocks in the Major Telecommunications Industry was 2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -14%. LBTYA experienced the highest price growth at 25%, while FNGR experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Major Telecommunications Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was 12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 57
Price Growth Rating: 63
SMR Rating: 72
Profit Risk Rating: 83
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of telecommunications products and services

Industry MajorTelecommunications

Industry
Major Telecommunications
Address
510 West Georgia Street
Phone
+1 604 697-8044
Employees
55000
Web
https://www.telus.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
RBLX shares plunged approximately 24% in premarket trading on Friday, May 1, 2026, falling roughly $13.36 to around $41.90 from the prior close of approximately $55.26. The primary catalyst was a dramatic cut to full-year 2026 bookings guidance, slashed to $7.33B–$7.60B from $8.28B–$8.55B.
SMMT shares fell approximately 20% in premarket trading on Friday, May 1, 2026, dropping from a prior close of approximately $20.83 to around $16.66. The primary catalyst was the HARMONi-3 interim PFS analysis miss, with the Phase III global trial failing to meet expectations for its squamous cohort, undermining the ivonescimab thesis.